Singapura - Inggris - HSA (Health Sciences Authority)

ferring pharmaceuticals private limited - obstetrics & gynaecology - reusable injection pen intended for the administration of subcutaneous injections of rekovelle provided by ferring pharmaceuticals a/s.

Filipina - Inggris - FDA (Food And Drug Administration)

akums drugs & pharmaceuticals ltd. (plant iii-injectables) - drug - metronidazole - promeddazole

Filipina - Inggris - FDA (Food And Drug Administration)

metz pharmaceuticals, inc. - ascorbic acid , cholecalciferol , zinc - capsule classification: over-the-counter (otc) - 500 mg (equivalent to 562.43 mg sodium ascorbate) 1,000 iu/10 mg (equivalent to 70 mg zinc gluconate) dosage

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

essential pharmaceuticals limited - clobazam - oral suspension - 1 milligram(s)/millilitre - clobazam

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - 61215 - pharmaceutical management support software - clopine central is a web-based application intended for the remote monitoring of agranulocytosis or neutropenia, via completion of regular blood testing, as reported by medical practitioners for patients affected by treatment resistant schizophrenia.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - 64410 - pharmaceutical management support software, professional-use - manage-pd device is a software-based tool intended to support healthcare providers in the identification of patients with parkinson's disease (pd) uncontrolled on oral medications.

Uni Eropa - Inggris - EMA (European Medicines Agency)

mylan pharmaceuticals limited - febuxostat - hyperuricemia; arthritis, gouty; gout - antigout preparations - febuxostat mylan is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of tumor lysis syndrome (tls).febuxostat mylan is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).febuxostat mylan is indicated in adults.

Uni Eropa - Inggris - EMA (European Medicines Agency)

mylan pharmaceuticals limited - cinacalcet hydrochloride - hyperparathyroidism, secondary; hypercalcemia - calcium homeostasis - treatment of secondary hyperparathyroidism (hpt) in patients with end-stage renal disease (esrd) on maintenance dialysis therapy.cinacalcet mylan may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate.reduction of hypercalcaemia in patients with:parathyroid carcinomaprimary hpt for whom parathyroidectomywould be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated. 

Uni Eropa - Inggris - EMA (European Medicines Agency)

mylan pharmaceuticals limited - duloxetine - neuralgia; diabetic neuropathies; depressive disorder, major; anxiety disorders - psychoanaleptics, - treatment of major depressive disorder;treatment of diabetic peripheral neuropathic pain;treatment of generalised anxiety disorder;duloxetine mylan is indicated in adults.

Uni Eropa - Inggris - EMA (European Medicines Agency)

mylan pharmaceuticals limited - deferasirox - iron overload; beta-thalassemia - iron chelating agents - deferasirox mylan is indicated forthe treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and olderthe treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (